Novo Nordisk A/S (NVO)
41.65
+1.00
(+2.46%)
USD |
NYSE |
Nov 13, 16:00
41.48
-0.17
(-0.41%)
After-Hours: 18:18
Novo Nordisk Net Income (Quarterly) : 2.576B for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.576B |
| June 30, 2026 | 3.265B |
| March 31, 2026 | 7.604B |
| December 31, 2025 | 4.191B |
| September 30, 2025 | 3.133B |
| June 30, 2025 | 4.026B |
| March 31, 2025 | 4.096B |
| December 31, 2024 | 4.037B |
| September 30, 2024 | 4.020B |
| June 30, 2024 | 2.894B |
| March 31, 2024 | 3.698B |
| December 31, 2023 | 3.167B |
| September 30, 2023 | 3.281B |
| June 30, 2023 | 2.838B |
| March 31, 2023 | 2.856B |
| December 31, 2022 | 1.864B |
| September 30, 2022 | 1.949B |
| June 30, 2022 | 1.905B |
| March 31, 2022 | 2.142B |
| December 31, 2021 | 1.674B |
| September 30, 2021 | 1.921B |
| June 30, 2021 | 1.965B |
| March 31, 2021 | 2.044B |
| December 31, 2020 | 1.492B |
| September 30, 2020 | 1.617B |
| Date | Value |
|---|---|
| June 30, 2020 | 1.569B |
| March 31, 2020 | 1.754B |
| December 31, 2019 | 1.292B |
| September 30, 2019 | 1.519B |
| June 30, 2019 | 1.444B |
| March 31, 2019 | 1.589B |
| December 31, 2018 | 1.299B |
| September 30, 2018 | 1.410B |
| June 30, 2018 | 1.654B |
| March 31, 2018 | 1.774B |
| December 31, 2017 | 1.306B |
| September 30, 2017 | 1.543B |
| June 30, 2017 | 1.473B |
| March 31, 2017 | 1.456B |
| December 31, 2016 | 1.260B |
| September 30, 2016 | 1.470B |
| June 30, 2016 | 1.513B |
| March 31, 2016 | 1.397B |
| December 31, 2015 | 1.212B |
| September 30, 2015 | 1.249B |
| June 30, 2015 | 1.237B |
| March 31, 2015 | 1.490B |
| December 31, 2014 | 1.096B |
| September 30, 2014 | 1.156B |
| June 30, 2014 | 1.285B |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AstraZeneca PLC | 3.076B |
| GSK Plc | 2.289B |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 6.451B |
| Merck & Co., Inc. | 5.067B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 12.19B |
| Total Expenses (Quarterly) | 9.612B |
| EPS Diluted (Quarterly) | 0.5825 |
| Enterprise Value | 149.40B |
| Gross Profit Margin (Quarterly) | 82.10% |
| Profit Margin (Quarterly) | 21.14% |
| Earnings Yield | 9.53% |
| Operating Earnings Yield | 13.57% |
| Normalized Earnings Yield | 10.56 |